Key facts
- This page summarizes Robert E. Landry's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Sep 2021, 16:05.
Robert E. Landry - 31 Aug 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)
- Reporting relationship
- EVP Finance CFO
- Issuer ticker
- REGN
- Reported as of
- 31 Aug 2021
- Net transaction value
- -$63,333
- SEC form
- 4
- Accepted by SEC
- 01 Sep 2021, 16:05:39 UTC
- Prior SEC filing
- 10 Aug 2021
- Next SEC filing
- 18 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/** Robert E. Landry
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Landry filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 01 Sep 2021.
Change
- Previous filing in this sequence was filed on 10 Aug 2021.
- Current net transaction value: -$63,333.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
REGN
transaction
Common Stock
Options Exercise
- Transaction value
- $555,670
- Shares
- +1,000
- Change %
- +3.9%
- Price
- $555.67
- Shares after
- 26,903
- Date
- 31 Aug 2021
- Ownership
- Direct
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $619,003
- Shares
- -917
- Change %
- -3.4%
- Price
- $675.03
- Shares after
- 25,986
- Date
- 31 Aug 2021
- Ownership
- Direct
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 229
- Date
- 31 Aug 2021
- Ownership
- By 401(k) Plan
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
REGN
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,000
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 4,000
- Date
- 31 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000
- Exercise price
- $555.67
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option award vests in four equal annual installments, commencing one year after the date of grant.